Allergen immunotherapy (AIT)-induced anaphylaxis is rare and more likely to result from subcutaneous vs sublingual immunotherapy (SCIT vs SLIT).

Lundbeck has stopped development of a subcutaneous formulation of its migraine drug Lu AG09222 as the Danish drugmaker ...

Rani Therapeutics Holdings, Inc. (“Rani Therapeutics” or “Rani”) (Nasdaq: RANI), a clinical-stage biotherapeutics company ...

EMA committee recommends approval of Bristol Myers Squibb’s subcutaneous formulation of Opdivo across multiple solid tumour indications: Princeton, New Jersey Monday, March 31, ...

Princeton: Bristol Myers Squibb has announced that the Committee for Medicinal Products for Human Use (CHMP) of the European ...

Merck’s pembrolizumab with berahyaluronidase alfa demonstrates noninferior PK compared to IV Keytruda in pivotal 3475A-D77 trial: Rahway, New Jersey Saturday, March 29, 2025, 10 ...

Merck has shared data from the pivotal Phase 3 trial evaluating the subcutaneous administration of pembrolizumab together ...

Bristol Myers (BMY) announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has recommended approval ...

Bristol Myers Squibb Receives Positive CHMP Opinion for the Subcutaneous Formulation of Opdivo® (nivolumab) Across Multiple Solid Tumor Indications ...

Merck released phase III data for an injection form of its blockbuster cancer treatment drug Keytruda and announced the FDA ...

The "Needle Free Drug Delivery Devices Market Industry Trends and Forecasts to 2035 -- Distribution by Type of Device, Route ...

HORSHAM, PA — Johnson & Johnson (NYSE: JNJ) has announced that the U.S. Food and Drug Administration (FDA) has approved ...